Purpose {#S0001}
=======

Accelerated partial breast irradiation (APBI) offers several benefits over conventional radiation techniques in the adjuvant treatment of early stage breast cancer for women undergoing breast-conserving surgery. From a patient perspective, APBI is more convenient and less time consuming than the standard 6 weeks conventional whole breast irradiation. These factors are even more pronounced for patients residing long distances from the treatment center \[[@CIT0001]\]. APBI has been delivered via interstitial multi-catheter brachytherapy as well as with single-entry single lumen applicators and single-entry hybrid brachytherapy applicators. Examples of these devices are the Mammosite^®^ (Hologic, Inc., Bedford, MA) single lumen applicator, the Mammosite^®^ multi-lumen applicator, the Contura^®^ (SenoRx, Inc., Irvine, CA) multi-lumen applicator \[[@CIT0002]\] and the SAVITM (Cianna Medical, Aliso Viejo, CA) multi-lumen applicator \[[@CIT0002]\].

Typical PTV expansions from the cavity are 1.5--2.0 cm for an interstitial implant and 1.0 cm for the single-entry single lumen and single-entry hybrid devices. The 1.0 cm treatment distance is in part supported by the studies of Imamura and Ohtake *et al*. \[[@CIT0003], [@CIT0004]\]. Imamura *et al*. \[[@CIT0003]\] examined 324 invasive ductal breast carcinoma cases divided into three age groups and assessed disease extension as well as proliferative activity of the tumor. Their study found that the maximum distance of ductal spread from the edge of the invasive focus was 8.32 mm for the 40--64 age group and 5.28 mm for patients 65 years and older. Ohtake *et al*. \[[@CIT0004]\] studied specimens from 20 patient quadrantectomies and found the maximum intraductal disease extension from the edge of the primary tumor to be 7.7 mm for patients 50 years and older. Indeed, the guidelines for selecting APBI brachytherapy candidates echo these findings. The American Society of Breast Surgeons (ASBS) guidelines \[[@CIT0005]\] indicate that patients with invasive ductal carcinoma or ductal carcinoma in-situ, age greater than or equal to 45, tumor size less than or equal to 3 cm, node negative and with negative surgical margins are the potential candidates for APBI brachytherapy. The American Brachytherapy guidelines (ABS) \[[@CIT0006]\] are more conservative than those of the ASBS in that the patient must be 50 years or older and only invasive ductal carcinomas are considered.

The Strut Adjust Volume Implant^®^ or SAVI™ is fashioned in 4 different configurations: a mini 6-1 (total of 7 catheters), a standard 6-1 (7 catheters), an 8-1 (9 catheters) and a 10-1 (11 catheters). It is a single-entry hybrid catheter and is the only device on the market that provides 7 or more catheters. This device was designed to be a single-entry alternative for interstitial breast brachytherapy where 10--30 catheters are inserted into the breast tissue for treatment. As is typical for single-entry APBI breast devices, the PTV is the cavity expanded by 1.0 cm avoiding the pectoralis muscle and 2--5 mm from the skin surface.

The aforementioned clinicopathological studies present limited data and it is possible that cancer cells may reside at distances larger than 7--8 mm, quoted by Imamura *et al*. \[[@CIT0003]\] and Ohtake *et al*. \[[@CIT0004]\]. In fact, Vicini *et al*. \[[@CIT0007]\] found residual carcinoma extending from 1.0 to 1.5 cm in 10% of the re-excision specimens in their study. Balloon based devices, in some patient cases may be able to treat to a larger expansion (\> 10 mm) due to tissue compression \[[@CIT0008]\]. The SAVI™ will not be able to compress tissue appreciably due to the strut based design. It is for this reason that we examined using expansions beyond the typical 1.0 cm to generate the PTV for patients treated with the SAVI™ device.

Material and methods {#S0002}
====================

Patient selection and treatment {#S20003}
-------------------------------

Thirty patients treated with the SAVI™ applicator were selected from our clinical database retrospectively. These thirty SAVI™ patient cases constituted the entirety of our currently treated SAVI™ patients. Each of these patients was enrolled in an investigational review board approved clinical protocol. This protocol was written to assess early and late sequelae from accelerated partial breast brachytherapy treatments. All patients were treated to 34 Gy in 10 fractions (BID), separated by 6 hours or greater, in less than 10 elapsed days on a Nucletron MicroSelectron v3 remote afterloader (Nucletron B.V., Veenendaal, the Netherlands).

Patient simulation {#S20004}
------------------

Patients were placed supine in a Vac-Loc (MedTec, Orange City, IA) immobilization cradle with both arms abducted above their head. Laser marks were placed on the patient to ensure inter-fraction setup reproducibility. The SAVI™ stylettes were removed from the catheters and 6F transfer tubes (Nucletron B.V., TH Veenendaal, the Netherlands) were then attached to each catheter at one end and the source position simulator on the other end. The source simulator (Nucletron B.V., TH Veenendaal, the Netherlands) was advanced to the end of each of the catheters of the SAVI™device to measure the indexer lengths. These measurements were entered into the treatment planning computer. All patients were scanned using a Lightspeed RT4 CT scanner (General Electric Healthcare Systems, Milwaukee, WI) at 120 kVp, 300 mA with a slice thickness of 1.25 mm. The patients were scanned to include the entire breast with a 2 cm margin superiorly and inferiorly. Upon completion of the scan, AP and lateral scout images were reviewed to determine the maximum expansion of the device. The minimum cavity to rib distance, minimum cavity to skin distance, and volume of the cavity were all measured and recorded. All CT images were then sent to the Nucletron Oncentra Masterplan version 3.3 (Nucletron B.V., TH Veenendaal, the Netherlands) treatment planning system for planning. The cavity was defined as the region delineated by the outermost extension of the struts of the SAVI™ device in contact with the patient.

Treatment planning -- contouring {#S20005}
--------------------------------

Contours of the organs at risk (OAR) and the target were generated using the tools available in the Nucletron Oncentra (Nucletron B.V., TH Veenendaal, the Netherlands) treatment planning system. The skin, ribs, and pectoralis major muscle were all contoured as OARs. The skin was generated by contracting the external surface of the patient by 2 mm to create a rind of tissue extending from the skin surface to 2 mm in depth. This 2 mm rind was then limited to the superior (left or right) quadrant of the body of the patient depending on which side the device was implanted. This was performed since it was felt that the skin should not be represented as simply a surface, but rather as extending in a finite distance within the tissue \[[@CIT0009]\]. In addition, throughout the treatment, the minimum distance from the periphery of the APBI device to the skin surface can decrease as postoperative swelling decreases. The 2 mm rind of skin yields a more accurate representation of the dose delivered to the skin. We chose only the involved quadrant of skin, since including the entire skin contour would bias our DVHs, due to a large volume of skin receiving a relatively small dose. Each rib was contoured as a separate organ and after the final treatment plan was completed, the rib receiving the maximum dose was chosen as the organ for analysis. The final OAR that was contoured was the pectoralis major muscle. Next, the cavity was contoured. The planning target volume (PTV_OPT) that was used for optimization of the plans was generated by expanding the cavity 1 cm in an isotropic manner and limiting it from the pectoralis muscle, ribs and 2 mm from the superficial skin surface. Subsequently, the planning target volume used to evaluate dose coverage (PTV_EVAL) was generated. This was accomplished by subtracting the cavity region of interest from the PTV_OPT region of interest to obtain a shell that expanded 1 cm around the cavity, but was limited by the pectoralis muscle, the ribs and 2 mm from the skin surface. The PTV_EVAL was edited to include any invaginated tissue between the struts. The PTV_EVAL was not expanded into the lungs. The volume of the PTV_EVAL was recorded in the assessment sheet. The air and seroma that were contiguous with the cavity were contoured as a single region of interest and the volume was recorded. The volume of the air and seroma was divided by the PTV_EVAL volume to determine non-conformance. If the non-conformance was within 5%, the planning continued. All contours were limited in the superior-inferior direction by the extent of the PTV_OPT in order to better standardize the contours.

Treatment planning {#S20006}
------------------

All patient plans were optimized with the IPSA optimization algorithm \[[@CIT0010]\]. A class solution was loaded as a starting point and then iteratively adjusted until our clinical goals were achieved. [Table 1](#T0001){ref-type="table"} lists our clinical goals for dose volume coverage for the PTV_EVAL as well as the OARs. These goals were derived from the NSABP B-39 RTOG 0419 protocol \[[@CIT0011]\], previously published planning recommendations for the SAVI™ device \[[@CIT0012]\] and our clinical experience. The goals for the PTV_EVAL_1.5 and PTV_EVAL_1.25 plans were derived as a compromise between the NSABP B-39 RTOG 0419 protocol, published planning recommendations for the SAVI™ device \[[@CIT0012]\] and dose volume side effect response data of Wazer *et al*. \[[@CIT0013]--[@CIT0015]\].

###### 

Planning guidelines that were used to generate the treatment plans

  Treatment Planning Goals                                Acceptable Dose Constraints
  ------------------------------------------------------- -------------------------------------------------------
  V95 ≥95% for PTV_EVAL                                   V90 ≥90% for PTV_EVAL
  V90 ≥90% for PTV_EVAL_1.5                               V90 ≥90% for PTV_EVAL_1.5
  V150 ≤50 cc for PTV_EVAL                                V150 ≤50 cc for PTV_EVAL
  V150 ≤52.5 cc                                           V150 ≤52.5 cc
  for PTV_EVAL_1.5[2](#TF0002){ref-type="table-fn"}       for PTV_EVAL_1.5[2](#TF0002){ref-type="table-fn"}
  V200 ≤20 cc for PTV_EVAL                                V200 ≤20 cc for PTV_EVAL
  V200 ≤21 cc                                             V200 ≤21 cc
  for PTV_EVAL_1.5[2](#TF0002){ref-type="table-fn"}       for PTV_EVAL_1.5[2](#TF0002){ref-type="table-fn"}
  Max dose[1](#TF0001){ref-type="table-fn"} ≤100% of Rx   Max dose[1](#TF0001){ref-type="table-fn"} ≤125% of Rx
  dose for skin and rib                                   dose for skin and rib

Maximum dose was defined as the 0.1 cc of OAR receiving the highest dose.

Based on a compromise between NSABP B-39/ RTOG 0413, manufacturer recommendations \[[@CIT0012]\], and dose response data of Wazer \[[@CIT0013]--[@CIT0015]\]

At least two plans were generated for each patient. All clinical plans had a 1.0 cm PTV_EVAL (PTV_EVAL) expansion. Subsequent to the clinical plan, a 1.5 cm PTV_EVAL expansion was generated. This 1.5 cm PTV_EVAL (PTV_EVAL_1.5) expansion was created in similar fashion as the 1.0 cm PTV_EVAL; the cavity was expanded 1.5 cm isotropically and limited by the ribs, pectoralis major muscle and 2 mm in from the skin surface, while subtracting out the cavity. The PTV_EVAL_1.5 plans were optimized subject to the treatment planning goals in [Table 1](#T0001){ref-type="table"}. All PTV_EVAL_1.5 plans not meeting the goals in [Table 1](#T0001){ref-type="table"} were re-planned with a 1.25 cm PTV_EVAL expansion (PTV_EVAL_1.25). The PTV_EVAL_1.25 plans were optimized subject to identical treatment planning goals as the PTV_EVAL_1.5 plans.

Data analysis {#S20007}
-------------

For each treatment plan, the percentage of volume of PTV_EVAL, PTV_EVAL_1.25 and PTV_EVAL_1.5 receiving 306, 323, and 340 cGy, denoted by V90, V95, and V100, respectively, was extracted from each DVH. These values correspond to 90%, 95%, and 100% of the prescription dose. The volume of PTV_EVAL, PTV_EVAL_1.25 and PTV_EVAL_1.5 (cc) that received 150% and 200% of the prescription dose was then recorded. This was repeated for the OARs, except the% volumes extracted were 0.1 cc of the volume receiving the highest dose. The above data was collected also for the PTV_EVAL after optimizing the PTV_EVAL_1.5 to achieve V90 of 90% of the PTV_EVAL_1.5 volume. This was performed to assure that the original PTV_EVAL coverage and OAR maximum doses were still acceptable. Comparisons between OAR maximum doses (0.1 cc) (1.0 cm PTV_EVAL OARs vs. either 1.25 or 1.5 cm PTV_EVAL OARs) were performed with a nonparametric Wilcoxon rank test. Differences were considered significant if the calculated p-value was less than or equal to 0.05. Matlab version 7.4 (the MathWorks, Inc., Natick, MA) was used to perform all statistical calculations. Non-conformance for the PTV_EVAL was extracted from each of the clinical plans and reported.

Results {#S0008}
=======

[Table 2](#T0002){ref-type="table"} displays the demographics of the 30 clinical plans. Coverage of 90% of the prescription dose of the PTV_EVAL in all cases exceeded 97% of the volume. Coverage of 95% of the prescription dose of the PTV_EVAL in all cases exceeded 94.7% of the volume. Median V150 and V200 volumes were 31.0 cc and 14.2 cc, respectively. The median maximum skin dose was 105.7% of the prescription dose. The median maximum rib dose was 97.4% of the prescription dose. The median non-conformance over all 30 patient plans was 0.7%, whereas it was 0.85%, 0.75%, and 0.3% for the 6-1, 8-1, and 10-1 device groups, respectively. The distance from the SAVI™device to skin and ribs ranged from 1.0 mm to 33.5 mm over the patient cohort. [Table 3](#T0003){ref-type="table"} displays the demographics of the PTV_EVAL_1.5 plans that met the criteria in [Table 1](#T0001){ref-type="table"}. Nine cases (30% of the total number of cases) met the criteria established in [Table 1](#T0001){ref-type="table"}. Zero of four 6-1 (0%), six of fifteen 8-1 (40%), and three of eleven 10-1 (27%) cases were expanded to a 1.5 cm PTV_EVAL successfully. Coverage of 90% of the prescription dose of the PTV_EVAL_1.5 in all cases exceeded 90.2% of the volume. Coverage of 95% of the prescription dose of the PTV_EVAL_1.5 in all cases exceeded 85.8% of the volume. The median volume of the PTV_EVAL increased by 41.7 cc (37%) and 60 cc (59%), for the 8-1 and 10-1 applicators, respectively. Median V150 and V200 volumes were 39.2 cc and 19.3 cc, respectively. The median maximum skin dose was 114.2% of the prescription dose. The 1.5 cm PTV_EVAL maximum skin doses did not differ statistically from the 1.0 cm PTV_EVAL maximum skin doses (*p*≤0.36). The median maximum rib dose was 117.6% of the prescription dose. The 1.5 cm PTV_EVAL maximum rib doses did not differ statistically from the 1.0 cm PTV_EVAL maximum rib doses (*p*≥0.11). Coverage of the PTV_EVAL volume increased post optimization of the PTV_EVAL_1.5; as the median coverage of 90%, 95% and 100% of the prescription dose of the PTV_EVAL was 99.9%, 98.9%, and 96.7% of the volume, respectively. The V150 and V200 median volumes for the PTV_EVAL post PTV_EVAL_1.5 optimization were 34.4 cc and 19.3 cc, respectively.

###### 

Demographics of the clinical plans. Values in the cells represent the median over the patient population. Values in the parenthesis indicate the number of patient cases for each applicator size

  Device      Cavity (cc)   PTV_EVAL (cc)   V90%   V95%   V150% (cc)   V200% (cc)   Skin% (0.1 cc)   Rib% (0.1 cc)
  ----------- ------------- --------------- ------ ------ ------------ ------------ ---------------- ---------------
  6-1 (4)     15.7          54.4            97.4   94.7   25.9         12.7         103.7            82.2
  8-1 (15)    33.1          70.5            98.7   96.7   31.0         14.2         105.7            97.4
  10-1 (11)   51.3          102.2           98.5   95.8   43.0         18.2         100.6            92.7

###### 

Demographics of the 1.5 cm PTV_EVAL plans that met V150% and V200% criteria of 52.5 cc and 21 cc, respectively (criteria based on a compromise between NSABP B-39/RTOG 0413, manufacturer recommendations \[[@CIT0012]\] and dose response data of Wazer \[[@CIT0013]--[@CIT0015]\]). Values in the cells represent the median over the patient population. Values in parenthesis indicate the number of plans meeting the criteria

  Device     PTV_EVAL_1.5 (cc)   V90%   V95%   V150% (cc)   V200% (cc)   Skin% (0.1 cc)   Rib% (0.1 cc)
  ---------- ------------------- ------ ------ ------------ ------------ ---------------- ---------------
  6-1 (0)    --                  --     --     --           --           --               --
  8-1 (6)    112.2               90.4   86.1   35.8         18.5         114.2            106.4
  10-1 (3)   162.2               90.2   85.8   44.0         20.2         110.2            117.6

[Table 4](#T0004){ref-type="table"} displays the demographics of the PTV_EVAL\_ \_1.25 plans that met the criteria in [Table 1](#T0001){ref-type="table"}. This group was composed of the remainder of the cases (21) from the PTV_EVAL_1.5 group that did not meet the criteria established in [Table 1](#T0001){ref-type="table"}. All 21 cases met the criteria showed in [Table 1](#T0001){ref-type="table"}. Coverage of 90% of the prescription dose of the PTV_EVAL_1.25 in all cases exceeded 93.7% of the volume. Coverage of 95% of the prescription dose of the PTV\_ \_EVAL_1.25 in all cases exceeded 87.4% of the volume. Median volume of the PTV_EVAL increased by 16 cc (29%), 24.9 cc (35%), and 33.5 cc (33%), for the 6-1, 8-1, and 10-1 applicators, respectively. Median V150 and V200 volumes were 41.2 cc and 19.3 cc, respectively. The median maximum skin dose was 109.2% of the prescription dose. The 1.25 cm PTV_EVAL maximum skin doses did differ statistically from the 1.0 cm PTV_EVAL maximum skin doses (*p*≥0.02). However, the median maximum skin dose for the 1.25 cm PTV_EVAL actually decreased for the 10-1 subgroup of patients. The median maximum rib dose was 102.5% of the prescription dose. The 1.25 cm PTV_EVAL maximum rib doses did not differ statistically from the 1.0 cm PTV_EVAL maximum rib doses (*p*≥0.76).

###### 

Patient case demographics of the 1.25 cm PTV_EVAL plans. Values in the cells represent the median over the patient population. Values in parenthesis indicate the number of plans meeting the V150% and V200% criteria of 52.5 cc and 21 cc, respectively (criteria based on a compromise between NSABP B-39/RTOG 0413, manufacturer recommendations \[[@CIT0012]\] and dose response data of Wazer \[[@CIT0013]--[@CIT0015]\])

  Device     PTV_EVAL_1.5 (cc)   V90%   V95%   V150% (cc)   V200% (cc)   Skin% (0.1 cc)   Rib% (0.1 cc)
  ---------- ------------------- ------ ------ ------------ ------------ ---------------- ---------------
  6-1 (4)    70.4                95.2   92.1   35.3         19.5         105.8            96.5
  8-1 (9)    95.4                94.0   90.5   39.8         18.8         109.2            102.5
  10-1 (8)   135.7               93.4   87.4   48.7         19.9         98.1             84.9

Discussion {#S0009}
==========

The question as to whether it is dosimetrically possible to treat to a 1.25 cm or 1.5 cm expansion of the cavity with a commercial single-entry multi-catheter APBI brachytherapy device was examined. All patients in this study could have been treated with a 1.25 cm expansion of their cavity. 30% of this patient cohort could have been treated with a 1.5 cm expansion of the cavity. OARs did not experience a statistically significant increase in median dose except for the 1.25 cm PTV_EVAL skin maximum dose. This difference could be due to the small sample size. However, the 1.25 cm PTV_EVAL median maximum skin dose was still within the NSABP B-39/ RTOG 0413 guidelines for acceptable skin doses of 145% of prescribed dose to the skin surface. In addition, the median maximum skin dose was below the 125% of prescribed dose to the skin surface recommended by other single-entry hybrid breast brachytherapy devices.

Several patient groups may benefit from an increased PTV_EVAL volume. Holland *et al*. \[[@CIT0016]\] found noninvasive carcinoma within 2 cm or greater from the primary tumor in 75% of 282 of invasive carcinomas with tumor size ≤5 cm and 37% of 130 tumors 2 cm or less. So, treating beyond the typical 1.0 cm PTV_EVAL expansion may benefit currently accepted patients. The longest efficacy data with APBI is in patients treated with multi-catheter interstitial brachytherapy. The targeted breast tissue was 1--2 cm beyond the lumpectomy bed in the patients treated at William Beaumont Hospital \[[@CIT0017]\]. In the RTOG 95-17 phase II trial of brachytherapy alone after lumpectomy, the treatment target was defined as a 2 cm margin peripheral to the surgical cavity and 1 cm anteriorly and posteriorly \[[@CIT0018]\]. Ohtake *et al*. \[[@CIT0004]\] found intraductal extension for the age group of 40--49 yr old to have a maximum extent of 14.3 mm. Thus, it may be possible to treat a younger cohort of patients by expanding the cavity to a 1.25--1.5 cm PTV_EVAL. Patients that are not able to tolerate an interstitial breast brachytherapy implant or centers not equipped to handle such a procedure, may also benefit from treating to a 1.25--1.5 cm PTV_EVAL with the SAVI™device.

The limitations of this study are the sample size of thirty patients and the fact that this study only examined theoretical dosimetric aspects of treating beyond a 1.0 cm expansion of cavities. Larger sample sizes could predict with greater accuracy the unintended consequences of treating to a larger volume PTV_EVAL. We hypothesize that the consequences could be an increased risk of fat necrosis, skin reactions (e.g. telangiectasia) and rib fracture. The highest skin dose in the PTV_EVAL_1.25 and PTV_EVAL_1.5 groups that passed V150 and V200 criteria was 134% of the prescription dose. This value is less than the accepted highest dose recommended by NSABP B-39/RTOG 0413 of 145% of the prescription dose. Turesson *et al*. \[[@CIT0019]\] noted that telangiectasia risk increases with escalating dose above 40 Gy. However, based on current analysis and available data \[[@CIT0013]--[@CIT0015], [@CIT0020], [@CIT0021]\], the risk of these reactions is no different than treating with a 1.0 cm PTV_EVAL.

Conclusions {#S0010}
===========

It is dosimetrically possible to treat to beyond the currently advised 1.0 cm PTV_EVAL. Most patients should be able to be treated with a 1.25 cm PTV_EVAL and a select group with a 1.5 cm PTV_EVAL. Applicator size appears to determine the ability to expand to 1.5 cm PTV_EVAL as smaller devices (6-1) were not as propitious in this regard. Further studies may identify additional patient groups that would benefit from this approach. However, the clinical benefit, risks and toxicity can only be determined within the confines of an investigational review board clinical protocol.
